Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4432331 | 0.99 | MAPT (0.49) | TDP1MAPTFBP1VCAM1MEN1 | |
| SCHEMBL27919377 | 0.85 | TDP1 (0.44) | TDP1MAPTVCAM1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5710125 | 0.84 | TDP1 (0.43) | TDP1MAPTVCAM1MEN1KMT2A | |
| SCHEMBL6781270 | 0.83 | AKR1B1 (0.47) | MAPTFBP1MEN1KMT2ALMNA | |
| SCHEMBL273112 | 0.82 | LMNA (0.45) | TDP1MAPTFBP1VCAM1MEN1 | |
| SCHEMBL2476365 | 0.81 | TDP1 (0.40) | TDP1MAPTVCAM1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL273187 | 0.81 | LMNA (0.44) | TDP1MAPTFBP1VCAM1MEN1 | |
| SCHEMBL278949 | 0.81 | TDP1 (0.51) | TDP1MAPTVCAM1MEN1KMT2A | |
| SCHEMBL10603695 | 0.80 | ALDH1A1 (0.53) | TDP1MAPTMEN1KMT2ALMNA | |
| SCHEMBL2476369 | 0.79 | TDP1 (0.38) | TDP1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103333078-A | Synthesis method for key intermediate, analogue or salt of ticlopidine | SUZHOU HUIHE PHARMACEUTICAL CO LTD | 2013-10-02 | — | — | CN | claimed |
| CN-103180323-B | For the method preparing anagrelide and the like | 夏尔有限责任公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-103333078-B | The synthetic method of a kind of anagrelide key intermediate, analogue or its salt | SUZHOU HUIHE PHARMACEUTICAL CO., LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-103333078-B | The synthetic method of a kind of anagrelide key intermediate, analogue or its salt | SUZHOU HUIHE PHARMACEUTICAL CO., LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| US-9067944-B2 | Process for the preparation of anagrelide and analogues thereof | SHIRE LLC (US) | 2015-06-30 | — | — | US | disclosed |
| CN-103333078-A | Synthesis method for key intermediate, analogue or salt of ticlopidine | SUZHOU HUIHE PHARMACEUTICAL CO LTD | 2013-10-02 | — | — | CN | disclosed |
| CN-103333078-A | Synthesis method for key intermediate, analogue or salt of ticlopidine | SUZHOU HUIHE PHARMACEUTICAL CO LTD | 2013-10-02 | — | — | CN | disclosed |
| EP-2630148-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | Shire LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20130211083-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| CN-103180323-A | Process for the preparation of anagrelide and analogues thereof | SHIRE LLC | 2013-06-26 | — | — | CN | disclosed |
| WO-2012052781-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211083-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | CIAPIN1, QDPR, CYP51A1 | TDP1 1113/4885MAPT 4293/4885FBP1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.